Drawing for NATURE QUEEN

USPTO serial 87540974

NATURE QUEEN

Reviewed by CopyMark Law Group

Reg. 5591356Status 701Registered
Filing date
Status date
Registration date
Oct 23, 2018
Examiner
NEVILLE, BRIAN
Law office
Historical data usage

What this means

Status 701 means the registration is active and the first Section 8 declaration of continued use was accepted. The next major deadline is the combined Section 8 and Section 9 filing at the 10-year anniversary. Calendar the 10-year Section 8 and 9 combined renewal.

Status 701: Status 701 means the registration is active and the first Section 8 declaration of continued use was accepted. The next major deadline is the combined Section 8 and Section 9 filing at the 10-year anniversary.

Need help with NATURE QUEEN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Nazly Aileen Bayramoglu

Nazly Aileen Bayramoglu Bayramoglu Law Offices LLC1540 West Warm Springs Road, Suite 100Henderson, NV 89014United States

Goods and services

ClassDescriptionStatusFirst use
005[ Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; ] Pharmaceutical preparations for the treatment of musculo-skeletal disorders; [ Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of worms in pets; ] Pharmaceutical preparations for the treatment of infectious diseases; [ Pharmaceutical preparations for the treatment of heart rhythm disorders; ] Pharmaceutical preparations for the treatment of kidney diseases; [ Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations for the treatment of hormonal disorders ] and the prevention of osteoporosis; [ Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; ] Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; [ Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations and substances for the treatment of infectious diseases, ] blood disorders, pain, inflammation, [ sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, ] kidney diseases or disorders, [ and diabetes; ] Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; [ Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine,] musculoskeletal, cardiovascular, [ cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, ] neurological, gastrointestinal, [ hormonal, dermatological, psychiatric and immune system related diseases and disorders; ] Herbal supplements;[ Dietary supplements; ] Nutritional supplements [ ; Medicated soap; Disinfectant soap ]ACTIVEApr 2, 2018

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 22, 2026EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Jul 22, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jul 22, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 22, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 19, 2025NAS8NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED—
Aug 19, 20258.OKREGISTERED - SEC. 8 (6-YR) ACCEPTEDThe USPTO accepted your Section 8 declaration showing the mark is still in use in commerce (or excusable nonuse). This satisfies the six-year maintenance requirement and keeps the registration active until the next renewal deadline.
Aug 6, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Apr 22, 2025ES8RTEAS SECTION 8 RECEIVED—
Apr 18, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 18, 2025EWORTEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED—
Apr 18, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 18, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 18, 2025CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Apr 18, 2025COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Oct 23, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Mar 20, 2019TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 20, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 20, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 23, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 19, 2018SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Sep 18, 2018CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Aug 28, 2018SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Aug 28, 2018AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jul 30, 2018IUAFUSE AMENDMENT FILED—
Jul 30, 2018EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Jan 30, 2018NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Dec 5, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 5, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 15, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 30, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 23, 2017DOCKASSIGNED TO EXAMINER—
Jul 29, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 28, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance